Congress’ year-end spending deal states that FDA has authority to ban a medical device for one or more intended uses, potentially including off-label uses -- a move drug and device lawyers say has “far-reaching consequences” by essentially giving the agency power to regulate the practice of medicine. They view the provision as a sea change that could lay a precedent for FDA to also block patient access to off-label uses of prescription drugs. “[T]his provision erodes a bedrock principle: FDA...